ISRCTN10978180终止1 期
PAGoDA: A Phase Ib/IIa Trial Combining the Selective Dual Trk/CSF1R Kinase Inhibitor PLX7486 with Gemcitabine in Patients with Advanced Solid Tumours, or as First or Second-line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
HS Greater Glasgow and Clyde0 个研究点目标入组 30 人开始时间: 2018年2月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age = 16 years
- •2. Able to give written informed consent prior to participating in the trial and any trial related procedures being performed
- •3. Willingness to comply with scheduled visits, treatment plans, laboratory tests and other trial procedures
- •4. Karnofsky Performance Score = 70
- •5. Measurable or evaluable disease. Patient enrolled in the expansion phase should have measurable disease by RECIST v1.1 criteria
- •6. Dose escalation phase:
- •6.1. Patients with a histologically or cytologically proven advanced solid tumour refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient, and where treatment with gemcitabine is an appropriate option.
- •6.2. Any number of prior lines of therapy permitted
- •7. Dose expansion phase:
- •7.1. Patients with histologically or cytologically proven locally advanced or metastatic PDAC with the primary tumour in-situ, in whom single-agent gemcitabine is indicated, either as first-line palliative chemotherapy or second-line chemotherapy following FOLFIRINOX treatment. Previous FOLFIRINOX must be completed = 28 days prior to cycle 1 day
- •7.2. Patients who have an average cancer-related pain score of 3-8 on the Short Form Brief Pain Inventory within 3 weeks of Cycle 1 Day 1
- •8. Adequate haematological and biochemical indices as below performed within one week (Day -7 to Day 1) before the patient receives study drug (note: patients must not have received recent red blood cell transfusions within 4 weeks, platelet transfusions within 1 week, or growth factors within 1 week of screening tests)
- •9. Females of childbearing potential must have a negative pregnancy test within 7 days prior to start of dosing, agree to use adequate contraceptive measures (see section 7.1.7) from the time of the negative pregnancy test up to 6 months after the last dose of study drug, and should not be breast feeding. Non-childbearing potential must be evidenced by fulfilling one of the following criteria at screening:
- •9.1. Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments.
- •9.2. Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation
- •10. Male patients should be willing to use barrier contraception i.e. condoms and female partners of child bearing potential must agree to use adequate contraceptive measures for the duration of the study and up to 6 months after the completion of the study treatment
- •11. Able to swallow and absorb oral medications
- •12. Life expectancy of at least 12 weeks
排除标准
- •1. Any systemic anti-cancer therapy (including investigational medicinal products) within 21 days prior to cycle 1 day 1 (6 weeks for nitrosureas and Mitomycin-C); within 5 half-lives for biological therapy and within 14 days for palliative radiotherapy.
- •1.1. Dose expansion phase: Prior gemcitabine-based chemotherapy for advanced disease. Prior neo-/adjuvant gemcitabine completed = 6 months prior to cycle 1 day 1 is permitted.
- •2. Unresolved significant toxicity from prior therapy (except alopecia and Grade 1 toxicities, which in the opinion of the Investigator should not exclude patients). If uncertain, please contact the CTU to raise with the Chief Investigator.
- •3. Known leptomeningeal involvement, brain metastases or spinal cord compression, history of seizures or any condition that may predispose to seizure, including alcoholism
- •4. Known hypersensitivity (> Grade 2) to pyrimidine antimetabolites, PLX-7486 or structurally/ chemically similar drugs
- •5. Any gastrointestinal condition that may affect drug absorption of PLX-7486: malabsorption syndrome, previous gastrointestinal surgery (previous Whipples resection permitted), bowel obstruction, current refractory nausea or vomiting
- •6. Patients with uncontrolled diabetes
- •7. Treatment with warfarin. Patients on warfarin for DVT-PE can be converted to LMWH or oral Factor Xa inhibitors e.g. Rivaroxaban
- •8. Any severe or uncontrolled systemic disease (including active infection) or evidence of any other significant disorder or lab finding that the Investigator considers would make it undesirable for the patient to participate in the trial e.g. interstitial lung disease, severe hepatic impairment, uncontrolled chronic renal disease.
- •9. Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
- •10. Resting ECG with measurable QTcF = 450 msec (for males) or =470 msec (for females) at screening. Known Left ventricular (LV) dysfunction outside the institutional range of normal (testing not required)
- •11. Current malignancies other types, with the exception of adequately treated cone-biopsied in-situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy who have no evidence of that disease for the last 3 years are eligible for the study.
- •12. Patients participating in or planning to participate in another interventional clinical trial whilst on this study. Participation in an observational trial is acceptable.
- •13.In the Investigator’s opinion, any other condition which would not make the patient a good candidate for the clinical trial
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C MutatioAdvanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-503714-77-00Mirati Therapeutics Inc.137
进行中（未招募）
不适用
A phase II clinical trial on the combination of dabrafenib and trametinib for BRAF-inhibitor pretreated patients with advanced BRAF V600 mutant melanomaadvanced BRAF V600 mutant melanomaMedDRA version: 16.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: HLTClassification code 10027156Term: Skin melanomas (excl ocular)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10066600Term: Melanoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10027480Term: Metastatic malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004966-33-BEZ Brussel
进行中（未招募）
1 期
Research into a new treatment for children and young adults with diffuse midline gliomaEUCTR2022-000636-40-NLPacific Pediatric Neuro-Oncology Consortium (PNOC)324
招募中
2 期
PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of ProgressioDiffuse midline glioma'sHigh grade brain tumors10029211NL-OMON53539Prinses Máxima Centrum voor Kinderoncologie30
招募中
1 期
PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of ProgressioDiffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs)MedDRA version: 25.1Level: LLTClassification code: 10087678Term: Diffuse midline glioma H3K27M mutation Class: 100000004848MedDRA version: 21.1Level: PTClassification code: 10065443Term: Malignant glioma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10080666Term: Diffuse intrinsic pontine glioma Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10006143Term: Brain stem glioma Class: 100000004864CTIS2023-507598-16-00Prinses Maxima Centrum voor Kinderoncologie B.V.324